Traws Pharma Begins Phase 2 Trials of Ritonavir-Free COVID Treatment Ratutrelvir, Results Expected by Year-End 2025
I'm PortAI, I can summarize articles.
Traws Pharma Inc. has initiated two Phase 2 clinical trials for ratutrelvir, a ritonavir-free antiviral treatment for COVID-19. One trial compares ratutrelvir to PAXLOVID® for safety and efficacy, while the other focuses on patients ineligible for PAXLOVID®. Results from both studies are expected by the end of 2025. No results have been released yet.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments